Novo Nordisk Navigates Milestone Approval Amid Investor Scrutiny

This week presented a study in contrasts for Novo Nordisk. The pharmaceutical giant achieved a significant regulatory breakthrough with one hand while facing pointed questions from shareholders with the other. These developments unfold against a backdrop of mounting pressure on the company's leadership to restore confidence following recent setbacks.

Shareholder Meeting Highlights Dividends and Board Changes

On March 26, the company held its Annual General Meeting, where several key resolutions were passed. Shareholders approved a final dividend for 2025 of 7.95 Danish kroner (DKK) per share. Combined with the interim dividend of 3.75 DKK, this brings the total annual payout to 11.70 DKK per share, marking a 2.6% increase from the previous year. The payout ratio stands at 50.7%. For investors holding NYSE-listed American Depositary Receipts (ADRs), this equates to approximately 1.2751 U.S. dollars per certificate, with payment scheduled for April 8, 2026.

The meeting also resulted in changes to the board of directors. Helena Saxon, Jan van de Winkel, and Ramona Sequeira were newly elected as members. Furthermore, Poul Weihrauch will join initially as an observer, with a proposal for his election as a full member slated for 2027. In a move concerning capital allocation, the board received authorization to repurchase up to 10% of the company's share capital. This is part of an ongoing buyback program, announced in February 2026, which allows for repurchases of up to 15 billion DKK over a twelve-month period.

FDA Greenlights Pioneering Weekly Insulin

In a major therapeutic advancement, the U.S. Food and Drug Administration (FDA) granted approval on March 27, 2026, for Awiqli® (insulin icodec-abae). This drug is the world's first and only once-weekly basal insulin injection. For individuals managing Type 2 diabetes, this innovation reduces the treatment burden from seven daily injections to just one per week.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

The approval is grounded in the comprehensive ONWARDS Phase 3a clinical program, which involved approximately 2,680 adult participants. Awiqli successfully met its primary endpoint of reducing HbA1c levels, demonstrating a safety profile consistent with the established basal insulin class. The medication had previously received regulatory clearance in the European Union and 13 other countries. Novo Nordisk plans to launch Awiqli in the crucial U.S. market in the second half of 2026.

Chief Executive Officer Mike Doustdar framed the approval as a strategic statement of commitment. At a time when some industry players are scaling back their insulin portfolios, he emphasized that Novo Nordisk is unequivocally reinforcing its dedication to this core therapeutic area.

Leadership Under Pressure to Regain Trust

Despite these positive announcements, a tense atmosphere was reported at the shareholder meeting. Chairman of the board Lars Rebien Sørensen faced intense scrutiny from investors; this was his first AGM since the leadership transition the previous year. The critical sentiment stems from two specific disappointments: the failed attempt to acquire an obesity-focused startup from Pfizer, and a 2026 financial forecast that fell short of market expectations.

Novo Nordisk at a turning point? This analysis reveals what investors need to know now.

The company's fourth-quarter report indicated that revenue in 2026 could decline by 5% to 13%, a steeper drop than most analysts had anticipated. The coming months will be a critical test for the new management team. The successful U.S. launch of Awiqli and the execution of the substantial share repurchase program are now viewed as key indicators of whether this leadership can engineer a turnaround and win back investor trust.

Ad

Novo Nordisk Stock: New Analysis - 30 March

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

DK0062498333 | NOVO | boerse | 69027261 |